News / Health

India's Cancer-Drug Ruling Likely to Have Global Impact

People gather at Novartis India headquarters in Mumbai April 1, 2013.
People gather at Novartis India headquarters in Mumbai April 1, 2013.
Jessica Berman
A landmark ruling by India’s high court this week struck down a bid by Swiss drugmaker Novartis to extend patent protection for its cancer drug, Glivec.

The decision is seen as a blow to Western pharmaceutical companies seeking to protect their financial interests.  Experts say it could embolden pharmaceutical companies in other countries hoping to produce generic versions of name-brand medications.  That could mean wider availability of the less expensive drugs throughout the developing world.

India is not the only country manufacturing generic versions of important and popular drugs.  Argentina and the Philippines have passed strict laws limiting the patent protections on name-brand drugs developed by U.S. and European pharmaceutical companies, including medications to treat HIV, the virus that causes AIDS.
 
Patents allow companies that develop a drug to maintain exclusive rights to sell it at a higher price for an extended period of time, in order to recoup their research and development costs.  Western pharmaceutical firms say those returns are essential to their ability to develop new and better medicines.

In the India case, which has been wending its way through the country’s judicial system for 7 years, Novartis failed to convince the high court that it had made changes to Glivec, its widely used leukemia drug, significant enough to warrant extending its patent and exclusive marketing rights.

Tahir Amin is a director of the New York-based Initiative for Medicines, Access and Knowledge, a non-profit organization which works on patent cases to increase access to drugs.  Amin says the India case is likely to have far-reaching implications.

“Globally, I think a number of countries will look at this and say, “Well India stood its ground,” and will also realize that actually if India is standing its ground, even though it has a stronger geopolitical standing and can actually probably stand up to the U.S. and Europe a little bit more, I think other countries will also take notice of this and say, 'This is in our public interest and health interest to adopt patent laws that are somewhat similar,'” said Amin.

India exports some $10 billion worth of generic drugs every year and, along with China, produces about 80 percent of the ingredients that are used in the manufacture of drugs in the United States. India also produces generic versions of many popular drugs.

Novartis and other drug companies say the Indian court ruling may force them to pull their research dollars out of India.

Mark Grayson is a spokesman for the Pharmaceutical Research and Manufacturers of America, or PhRMA, which represents drug manufacturers.
 
“We’re disappointed in this ruling because we believe that this just shows a further deteriorating innovation environment in India," said Grayson.

Generic drug versions can be sold at a fraction of the cost of brand-name drugs.  For example, Glivec can cost a patient around $70,000 a year, while the Indian generic versions costs around $2,500.
 
Grayson believes patients who can afford a drug like Glivec should pay full price.

“We believe we need to find ways to get economies that are growing to pay their fair share for the new medicines and the cost that it takes to develop a lot of this medicine," he said.

Grayson says 95 percent of the patients in India who can't afford Glivec can get it for free through a so-called "compassionate care" program run by Novartis.

But Tahir Amin of Initiatives for Medicine says cancer patients have reported that it has been difficult to obtain those free drugs.

“If you are going to be at the whim of philanthropy, then I think most people are not going to get drugs," he said. "And we’ve seen that in other cases as well, where they say we have access programs and so on and so forth.  But only a certain percentage of the population or countries get it.”

But with drug development costs sometimes topping $1 billion, PhRMA’s Grayson fears that India’s patent ruling and others that may follow could slow the pace at which critically needed new drugs come to market.

You May Like

US Firms Concerned About China's New Cyber Regulations

New rules would require technology companies doing business in financial sector to hand over their source code, adopt Chinese encryption algorithms More

WHO Focus on Ebola Shifts to Ending Outbreak

Focus to be less on building facilities and more on efforts to find infected people, manage their cases, engage with communities and ensure proper burials More

US Scientist Who Conceived of Groundbreaking Laser Technology Dies

Charles Townes, Nobel laureate, laser co-creator paved way for other scientific discoveries: CDs, eye surgery, metal cutters to name a few technologies that rely on lasers More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Super Bowl Ads Compete for Eyes on TV, Webi
X
January 29, 2015 9:58 AM
Super Bowl Sunday (Feb. 1) is about more than just the NFL's American football championship and big parties to watch the game. Viewers also tune in for the world famous commercials that send Facebook and Twitter abuzz. Daniela Schrier reports on the social media rewards for America’s priciest advertising.
Video

Video Super Bowl Ads Compete for Eyes on TV, Web

Super Bowl Sunday (Feb. 1) is about more than just the NFL's American football championship and big parties to watch the game. Viewers also tune in for the world famous commercials that send Facebook and Twitter abuzz. Daniela Schrier reports on the social media rewards for America’s priciest advertising.
Video

Video Theologians Cast Doubt on Morality of Drone Strikes

In 2006, stirred by photos of U.S. soldiers mistreating Iraqi prisoners, a group of American faith leaders and academics launched the National Religious Campaign Against Torture. It played an important role in getting Congress to investigate, and the president to ban, torture. VOA's Jerome Socolovsky reports.
Video

Video Freedom on Decline Worldwide, Report Says

The state of global freedom declined for the ninth consecutive year in 2014, according to global watchdog Freedom House's annual report released Wednesday. VOA's William Gallo has more.
Video

Video As Ground Shifts, Obama Reviews Middle East Strategy

The death of Saudi Arabia’s king, the collapse of a U.S.-friendly government in Yemen and a problematic relationship with Israel’s leadership are presenting a new set of complications for the Obama administration and its Middle East policy. Not only is the U.S. leader dealing with adversaries in Iran, the Islamic State and al-Qaida, but he is now juggling trouble with traditional allies, as White House correspondent Luis Ramirez reports.
Video

Video MRI Seems to Help Diagnose Prostate Cancer, Preliminary Study Shows

Just as with mammography used to detect breast cancer, there's a lot of controversy about tests used to diagnose prostate cancer. Fortunately, a new study shows doctors may now have a more reliable way to diagnose prostate cancer for high risk patients. More from VOA's Carol Pearson.
Video

Video Smartphones About to Make Leap, Carry Basic Senses

Long-distance communication contains mostly sounds and pictures - for now. But scientists in Britain say they are close to creating additions for our smartphones that will make it possible to send taste, smell and even a basic touch. VOA’s George Putic reports.
Video

Video NASA Monitors Earth’s Vital Signs From Space

The U.S. space agency, NASA, is wrapping up its busiest 12-month period in more than a decade, with three missions launched in 2014 and two this month, one in early January and the fifth scheduled for January 29. As VOA’s Rosanne Skirble reports, the instruments being lifted into orbit are focused on Earth’s vital life support systems and how they are responding to a warmer planet.
Video

Video Saved By a Mistake - an Auschwitz Survivor's Story

Dagmar Lieblova was 14 when she arrived at Auschwitz in December 1943, along with her entire Czech Jewish family. All of them were to die there, but she was able to leave after several months due to a bureaucratic mix-up which saved her life. Now 85, with three children and six grandchildren, she says she has a feeling of victory. This report by Ahmad Wadiei and Farin Assemi, of RFE/RL's Radio Farda is narrated by RFE’s Raymond Furlong.

Circumventing Censorship

An Internet Primer for Healthy Web Habits

As surveillance and censoring technologies advance, so, too, do new tools for your computer or mobile device that help protect your privacy and break through Internet censorship.
More

All About America

AppleAndroid